Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland

被引:87
作者
Chuang, YC
Huang, CC
Kang, HY
Chiang, PH
Demiguel, F
Yoshimura, N
Chancellor, MB
机构
[1] Chang Gung Mem Hosp, Dept Urol, Kaohsiung, Taiwan
[2] Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan
[3] Chang Gung Mem Hosp, Ctr Menopause & Reprod Med Res, Kaohsiung, Taiwan
[4] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA
关键词
prostate; botulinum toxin type A; rats; Sprague-Dawley; prostatic hyperplasia; receptors; adrenergic;
D O I
10.1016/S0022-5347(05)00318-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Intraprostatic injection of BTX-A has demonstrated clinical improvement in men with bladder outlet obstruction. We investigated the mechanisms of action of BTX-A on the prostate. Materials and Methods: Adult male Sprague-Dawley rats were injected with varying doses of BTX-A into the prostate and the prostates were harvested after 1 or 2 weeks. The effects of BTX-A on prostate histology, and the proliferative and apoptotic indexes were determined using hematoxylin and eosin staining, proliferative cell nuclear antigen staining and TUNEL staining, respectively. Changes in alpha(1A) adrenergic receptor and androgen receptor were evaluated by Western blotting. Results: One week after BTX-A injection generalized prostate atrophy was observed. There was a significant increase in apoptotic cells (12, 16 and 22-fold), and decrease in proliferative cells (38%, 77% and 80%) and alpha(1A) adrenergic receptor (13%, 80% and 81%) for 5, 10 and 20 U, respectively. There was no significant change in androgen receptors. The effects were decreased 2 weeks after BTX-A treatment. Conclusions: BTX-A injection into the prostate alters cellular dynamics by inducing apoptosis, inhibiting proliferation and down-regulating a,, adrenergic receptors. BTX-A may potentially be the drug that has dual actions on the static and dynamic components of benign prostatic hyperplasia.
引用
收藏
页码:1158 / 1163
页数:6
相关论文
共 20 条
[2]  
Chuang YC, 2004, J UROLOGY, V172, P1529, DOI 10.1097/01.ju.0000137844.77524.97
[3]  
COFFEY DS, 1990, UROL CLIN N AM, V17, P461
[4]   Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms [J].
De La Rosette, JJMCH ;
Kortmann, BBM ;
Rossi, C ;
Sonke, GS ;
Floratos, DL ;
Kiemeney, LALM .
JOURNAL OF UROLOGY, 2002, 167 (04) :1734-1738
[5]  
Doggweiler R, 1998, PROSTATE, V37, P44
[6]   Effects of chronic administration of doxazosin on α1-adrenoceptors in the rat prostate [J].
Foster, HE ;
Yono, M ;
Shin, D ;
Takahashi, W ;
Pouresmail, M ;
Afiatpour, P ;
Latifpour, J .
JOURNAL OF UROLOGY, 2004, 172 (06) :2465-2470
[7]   29-WEEK DOXAZOSIN TREATMENT IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY [J].
HOLME, JB ;
CHRISTENSEN, MM ;
RASMUSSEN, PC ;
JACOBSEN, F ;
NIELSEN, J ;
NORGAARD, JP ;
OLESEN, S ;
NOER, I ;
WOLF, H ;
HUSTED, SE .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, 28 (01) :77-82
[8]   Botulinum a toxin urethral injection for the treatment of lower urinary tract dysfunction [J].
Kuo, HC .
JOURNAL OF UROLOGY, 2003, 170 (05) :1908-1912
[9]  
Kyprianou N, 2000, PROSTATE, P42
[10]   Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia [J].
Kyprianou, N ;
Litvak, JP ;
Borkowski, A ;
Alexander, R ;
Jacobs, SC .
JOURNAL OF UROLOGY, 1998, 159 (06) :1810-1815